Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.42 |
| ▸ | PDE4A | P27815 | 8/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780055 | 0.88 | PDE10A (0.50) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL4780878 | 0.85 | MAOB (0.49) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL4781570 | 0.83 | PDE10A (0.36) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL4778874 | 0.83 | TP53 (0.46) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL4780116 | 0.76 | PDE10A (0.36) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL4781215 | 0.74 | MAOA (0.39) | PRMT5WDR77ROCK2ROCK1 | |
| SCHEMBL14310547 | 0.71 | PDE10A (0.51) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL14303843 | 0.71 | ROCK2 (0.34) | ROCK2ROCK1 | |
| SCHEMBL30123360 | 0.69 | PDE10A (0.51) | PDE10A | |
| SCHEMBL3271233 | 0.68 | PDE10A (0.76) | PDE10APDE4BPDE3BPDE3APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001182-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-01-03 | — | — | WO | claimed |
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| CN-115484938-A | Composition and use thereof | 博善人工智能剑桥有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2008001182-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001182-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | PDE10A 5/4885PDE4B 11/4885PDE3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.